Carlsmed secured $52.5 million in Series C funding to advance its AI-driven personalized surgery platform, targeting lumbar and cervical spine fusions.
Target Company Overview
Carlsmed is a cutting-edge Medtech company specializing in personalized surgery solutions powered by artificial intelligence. The company has developed the aprevo® platform, which focuses on improving outcomes specifically for spine surgeries, initially targeting lumbar fusion procedures with plans to expand to cervical fusions by 2025.
With the increasing demand for advanced surgical solutions that enhance patient outcomes, Carlsmed aims to leverage its AI technology to refine the surgical process, making it safer and more effective for patients through personalization.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in the United States
The Medtech industry in the United States is characterized by rapid innovation and significant investment, reflecting a robust growth trajectory. As healthcare technology evolves, there is a marked shift towards the imp
Similar Deals
Edwards Lifesciences → JenaValve Technology
2026
Fortified Health Security → Latitude Information Security
2026
LPOXY Therapeutics, Inc. → Xeno Biosciences Inc.
2025
B Capital, U.S. Venture Partners
invested in
Carlsmed
in 2024
in a Other deal
Disclosed details
Transaction Size: $53M